ArticleRomanian journal of ophthalmology
Angiotensin II and angiotensin converting enzyme: key players in the pathogenesis of hypertensive retinopathy.
Article in Romanian journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the association between hypertensive retinopathy (HR) and components of the renin-angiotensin system (RAS), specifically angiotensin II (Ang II) and angiotensin-converting enzyme (ACE), as potential biomarkers for the diagnosis and prognosis of HR. Methods: A total of 90 patients diagnosed primarily with hypertension were prospectively enrolled. HR was graded according to the Keith-Wagener-Barker classification into three severity groups. Paired serum and tear fluid samples were collected from each participant to measure Ang II and ACE levels, assessing both systemic and ocular changes. Statistical analyses included tests for normality and variance, as well as appropriate non-parametric methods. A p-value <0.05 was considered significant. Results: Serum Ang II levels increased significantly with advancing stages of HR (p=0.039), showing a 42% rise in moderate HR compared to mild HR and an additional 18% increase in severe HR. Tear Ang II levels decreased markedly from mild to moderate HR (p=0.022) and from mild to severe HR (p=0.028). Serum ACE levels rose significantly as HR progressed (p=0.032), notably between mild and moderate HR (66% increase, p=0.009), whereas tear ACE levels showed no significant differences. Discussion: Our findings showed that serum Ang II and ACE levels rise with HR severity, indicating systemic RAS activation, while tear Ang II decreases, suggesting altered local regulation. These contrasting trends reflect tissue-specific RAS activity and support the potential of Ang II as a biomarker for HR progression. The unchanged tear ACE levels imply limited ocular surface involvement. Overall, the data underscore RAS components' diagnostic relevance and therapeutic potential in hypertensive retinopathy. Conclusion: These findings suggest that Ang II levels in serum (increasing) and tears (decreasing) correlate with HR severity, while ACE changes are significant only in serum. Further studies are warranted to elucidate the role of RAS in HR pathophysiology and to explore its potential as a therapeutic target in ocular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.